semaglutide a Semaglutide: Weight Loss Breakthrough Semaglutide: Weight Loss and Diabetes

Vega D, Maalouf NM, Sakhaee K

For NAFLD-specific monitoring, patients with established liver disease may require additional specialist hepatology input, including non-invasive fibrosis assessment and consideration for liver imaging

Patient safety is central to any medical weight loss program

News provided by Eli Lilly and Company Dec 11, 2025, 06:45 ET In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks Retatrutide reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function, with more than 1 out of 8 retatrutide-treated patients completely free from knee pain at the end of the trial Seven additional Phase 3 trials evaluating the investigational once-weekly treatment in obesity and type 2 diabetes are expected to complete in 2026 INDIANAPOLIS, Dec

Are UTIs more common during dose escalation